Last reviewed · How we verify
NCT06582875
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
Phase 2 trial testing Tirzepatide in Autosomal Dominant Polycystic Kidney in 126 participants. Currently enrolling.
30 June 2029
Quick facts
| Lead sponsor | University of Colorado, Denver |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 126 |
| Start date | 6 March 2025 |
| Primary completion | 30 June 2029 |
| Estimated completion | 30 June 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Tirzepatide (TIRZEPATIDE) — full drug profile →
- Placebo
Conditions studied
- Autosomal Dominant Polycystic Kidney — all drugs for Autosomal Dominant Polycystic Kidney →
- Obesity — all drugs for Obesity →
Sponsor
University of Colorado, Denver
Who can join
Adults 18 to 65, any sex, with Autosomal Dominant Polycystic Kidney or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat and kidney metabolism using cutting-edge images techniques. Blood and urine samples will provide further insight into biological changes that may be linked to the benefits of the intervention, while ensuring careful monitoring of safety and tolerability.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment.
Salvador R, Moutinho CG, Sousa C, Vinha AF, et al · · 2025 · cited 9× · PMID 40143174 · DOI 10.3390/ph18030399 -
Can GLP-1 receptor agonists slow the progression of Autosomal Dominant Polycystic Kidney Disease?
Ali H, Alahmad B, Al-Mulla F. · · 2025 · PMID 40468228 · DOI 10.1186/s12882-025-04217-w
Verify or expand the search:
- PubMed search for NCT06582875
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tirzepatide
Trials testing the same drug.
- NCT07468552 — Trial of Tirzepatide for the Treatment of Cannabis Use Disorder · Phase 2 · not yet recruiting
- NCT06732245 — Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese · Phase 2 · not yet recruiting
- NCT07349641 — A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia · Phase 2 · not yet recruiting
- NCT07265752 — Tirzepatide for the Treatment of Cannabis Use Disorder · Phase 2 · not yet recruiting
- NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting
Other recruiting trials for Autosomal Dominant Polycystic Kidney
Currently open trials in the same condition.
- NCT06496542 — Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD · NA · active not recruiting
- NCT05478083 — A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease · Phase 2 · recruiting
- NCT04907799 — Daily Caloric Restriction in ADPKD · NA · active not recruiting
- NCT06759142 — Analysis of Patients With Autosomal Dominant Polycystic Kidney · recruiting
- NCT03273413 — Statin Therapy in Patients With Early Stage ADPKD · Phase 4 · active not recruiting
Other University of Colorado, Denver trials
Trials by the same sponsor.
- NCT07292285 — The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial. · not yet recruiting
- NCT07021937 — Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity · Phase 3 · not yet recruiting
- NCT07453732 — Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients. · NA · not yet recruiting
- NCT07038278 — 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma · EARLY_PHASE1 · not yet recruiting
- NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06582875 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Denver
- Last refreshed: 6 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06582875.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing